Popular weight loss drugs like Wegovy and Zepbound will soon cost Americans less under a new deal announced by President Donald Trump on Thursday.

Agreements with drugmakers Novo Nordisk and Eli Lilly will slash the prices of so-called GLP-1 drugs, which could eventually cost as little as $149 per month.

The average price of the blockbuster injectables will start at $350 per month on the administration's new TrumpRX platform but will trend down to $245 over the next two years, officials said Thursday.

"That's compared to roughly $500 today," Chris Klomp, director of Medicare and deputy administrator of the Centers for Medicare and Medicaid Services (CMS), said at a press conference.

The Medicare prices of Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound will be $

See Full Page